Lumos Accounts Payable from 2010 to 2024
| LUMO Stock | USD 4.30 0.01 0.23% |
Accounts Payable | First Reported 2009-12-31 | Previous Quarter 337 K | Current Value 1.5 M | Quarterly Volatility 4.1 M |
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
Lumos | Accounts Payable |
Latest Lumos Pharma's Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Lumos Pharma over the last few years. An accounting item on the balance sheet that represents Lumos Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lumos Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Lumos Pharma's Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Lumos Accounts Payable Regression Statistics
| Arithmetic Mean | 3,839,033 | |
| Geometric Mean | 1,411,114 | |
| Coefficient Of Variation | 165.78 | |
| Mean Deviation | 4,405,853 | |
| Median | 890,000 | |
| Standard Deviation | 6,364,316 | |
| Sample Variance | 40.5T | |
| Range | 22.6M | |
| R-Value | (0.18) | |
| Mean Square Error | 42.3T | |
| R-Squared | 0.03 | |
| Significance | 0.53 | |
| Slope | (252,227) | |
| Total Sum of Squares | 567.1T |
Lumos Accounts Payable History
About Lumos Pharma Financial Statements
Lumos Pharma investors utilize fundamental indicators, such as Accounts Payable, to predict how Lumos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 890 K | 845.5 K |
Check out the analysis of Lumos Pharma Correlation against competitors. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.